PREMARIN INTRAVENOUS POWDER FOR SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CONJUGATED ESTROGENS

Disponible des:

PFIZER CANADA ULC

Codi ATC:

G03CA57

Designació comuna internacional (DCI):

CONJUGATED ESTROGENS

Dosis:

25MG

formulario farmacéutico:

POWDER FOR SOLUTION

Composición:

CONJUGATED ESTROGENS 25MG

Vía de administración:

INTRAMUSCULAR

Unidades en paquete:

11 VIALS

tipo de receta:

Prescription

Área terapéutica:

ESTROGENS

Resumen del producto:

Active ingredient group (AIG) number: 0106442008; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2010-09-17

Fitxa tècnica

1
PRESCRIBING INFORMATION
PREMARIN
® INTRAVENOUS
(CONJUGATED ESTROGENS FOR INJECTION, C.S.D.)
25 MG CE/VIAL
ESTROGENIC HORMONES
® WYETH CANADA
DATE OF REVISION:
PFIZER CANADA INC., LICENSEE
MAY 14, 2019
17,300 TRANS-CANADA HIGHWAY
KIRKLAND, QUEBEC H9J 2M5
CONTROL #: 219416
2
TABLE OF CONTENTS
NAME OF DRUG
...........................................................................................................................3
PHARMACOLOGIC CLASSIFICATION
.....................................................................................3
ACTIONS AND CLINICAL PHARMACOLOGY
........................................................................3
INDICATIONS AND CLINICAL USE
..........................................................................................7
CONTRAINDICATIONS
...............................................................................................................7
WARNINGS
....................................................................................................................................8
PRECAUTIONS
............................................................................................................................11
DRUG INTERACTIONS
..............................................................................................................13
ADVERSE REACTIONS
..............................................................................................................14
DOSAGE AND ADMINISTRATION
..........................................................................................15
DIRECTIONS FOR STORAGE AND RECONSTITUTION
......................................................16
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................................16
PHARMACEUTICAL INFORMATION
......................................................................................17
AVAILABILITY OF DOSAGE FORMS
.....................................................................................17
PATIENT MEDICATION
INFORMATION.............